Total Valuation
Lotus Bio-Technology Development has a market cap or net worth of $783.00. The enterprise value is $8.07M.
Market Cap$783.00
Enterprise Value$8.07M
Share Statistics
Lotus Bio-Technology Development has 782,775,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding782,775,000
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Lotus Bio-Technology Development’s return on equity (ROE) is 0.32 and return on invested capital (ROIC) is 28.35%.
Return on Equity (ROE)0.32
Return on Assets (ROA)0.00
Return on Invested Capital (ROIC)28.35%
Return on Capital Employed (ROCE)0.24
Revenue Per Employee―
Profits Per Employee-10.00T>
Employee Count―
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Lotus Bio-Technology Development is ―. Lotus Bio-Technology Development’s PEG ratio is 6.06.
PE Ratio―
PS Ratio0.00
PB Ratio-189.02
Price to Fair Value-189.02
Price to FCF-652.69
Price to Operating Cash Flow-46.62
PEG Ratio6.06
Income Statement
In the last 12 months, Lotus Bio-Technology Development had revenue of 0.00 and earned -19.55K in profits. Earnings per share was >-0.01.
Revenue0.00
Gross Profit0.00
Operating Income-19.55K
Pretax Income-19.55K
Net Income-19.55K
EBITDA-19.55K
Earnings Per Share (EPS)>-0.01
Cash Flow
In the last 12 months, operating cash flow was 263.00 and capital expenditures 0.00, giving a free cash flow of 18.02K billion.
Operating Cash Flow263.00
Free Cash Flow18.02K
Free Cash Flow per Share<0.01
Dividends & Yields
Lotus Bio-Technology Development pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.00
52-Week Price Change0.00%
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)100.00
Average Volume (3m)0.00
Important Dates
Lotus Bio-Technology Development upcoming earnings date is Feb 13, 2018, Before Open (Confirmed).
Last Earnings DateInvalid Date
Next Earnings DateFeb 13, 2018
Ex-Dividend Date―
Financial Position
Lotus Bio-Technology Development as a current ratio of 0.00, with Debt / Equity ratio of -10.52%
Current Ratio0.00
Quick Ratio0.00
Debt to Market Cap<0.01
Net Debt to EBITDA-0.33
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Lotus Bio-Technology Development has paid 761.55K in taxes.
Income Tax761.55K
Effective Tax Rate-38.95
Enterprise Valuation
Lotus Bio-Technology Development EV to EBITDA ratio is -593.09, with an EV/FCF ratio of -653.05.
EV to Sales0.00
EV to EBITDA-593.09
EV to Free Cash Flow-653.05
EV to Operating Cash Flow-653.05
Balance Sheet
Lotus Bio-Technology Development has $50.01K in cash and marketable securities with $16.68K in debt, giving a net cash position of $33.32K billion.
Cash & Marketable Securities$50.01K
Total Debt$16.68K
Net Cash$33.32K
Net Cash Per Share<$0.01
Tangible Book Value Per Share>-$0.01
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Lotus Bio-Technology Development is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―